Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 18/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4002035 | 0.89 | MAOB (0.48) | MAOBGSK3BCYP2D6CYP1A2ALDH1A1 | |
| SCHEMBL3572942 | 0.87 | GSK3B (0.53) | MAOBGSK3BCYP2D6CYP1A2CSNK1A1 | |
| SCHEMBL3576362 | 0.86 | GSK3B (0.42) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL3572932 | 0.78 | GSK3B (0.44) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL3564673 | 0.78 | GSK3B (0.42) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3575962 | 0.78 | GSK3B (0.42) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL3579757 | 0.77 | GSK3B (0.42) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3574088 | 0.77 | GSK3B (0.46) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL3564794 | 0.76 | GSK3B (0.49) | GSK3BCYP2D6CYP1A2ALDH1A1 | |
| SCHEMBL3573554 | 0.76 | GSK3B (0.50) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781440-B2 | Use of substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | claimed |
| US-7388005-B2 | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo [1,2-a]pyrimidin-5(1H)one derivatives for neurodegenerative disorders | SANOFI-AVENTIS (FR) | 2008-06-17 | — | — | US | claimed |
| EP-1430056-B1 | SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES FOR NEURODEGENERATIVE DISORDERS | SANOFI AVENTIS (FR) | 2005-10-26 | — | — | EP | claimed |
| EP-1430056-A1 | SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES FOR NEURODEGENERATIVE DISORDERS | Sanofi-Aventis (FR) | 2004-06-23 | — | — | EP | claimed |
| WO-2003027115-A1 | SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES FOR NEURODEGENERATIVE DISORDERS | SANOFI-SYNTHELABO (FR) | 2003-04-03 | — | — | WO | claimed |
| EP-1430056-B1 | SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES FOR NEURODEGENERATIVE DISORDERS | SANOFI AVENTIS (FR) | 2005-10-26 | — | — | EP | disclosed |